BACKGROUND: The objective of the present study was to investigate the effectiveness of weekly @entity1311 administration in combination with oral @entity12749 in @entity1 with @entity263 refractory to hormonal manipulation. @entity1 AND METHODS: Between 1999 and 2000, 41 @entity1 were included in the study. All @entity1 had disease progression while on treatment with @entity1176 and antiandrogens. After being off hormonal therapy for at least 4 weeks, oral @entity12749 520 mg twice daily and 60 minutes @entity1311 60 mg/m2 once weekly, were administered. In total 152 courses were given (median 3.71). RESULTS: @entity137 was well-tolerated. The most common adverse effect was low-grade (I-II) @entity2359 . Objective partial responses were observed in 9 (22%) @entity1 ; when PSA decrease was included the total number of responders was 25 (61%) @entity1 . Median survival was 17 months (range 4-42+ months). CONCLUSION: Long-term median and overall survival was achieved in @entity1 with @entity263 refractory to hormonal treatment, with oral @entity12749 and weekly @entity1311 administration. @entity137 was acceptable.

Hormone refractory advanced @entity263 treated with @entity12749 and XXXX combination.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity12749 :: ('MESH:D004961', 'Chemical') :: ['estramustine'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1176 :: ('MESH:D007987', 'Chemical') :: ['LH-RH'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
